SUMMARY The electrocardiographic effects of imipramine hydrochloride at therapeutic plasma concentrations were determined in 44 depressed patients during a 6-week clinical outcome study of depression. Dur-ing each week of the protocol, i.e., 2 weeks of control and 4 weeks of drug treatment, a standard 12-lead ECG, high-speed, high-fidelity ECG tracings, and a 24-hour continuous ECG recording were obtained. PR, QRS, and QTc intervals, T-wave amplitude, heart rate and frequency of ventricular premature depolarizations (VPDs) were measured. The plasma concentration of imipramine and desmethylimipramine was measured three times a week. Imipramine prolonged the PR (p < 0.001), QRS (p < 0.001) and QTc (p < 0.001) intervals, increased the heart rate (p < 0.001) and lowered T-wave amplitude (p < 0.05) during the 4 weeks of treatment. No patient developed high-grade atrioventricular block or severe intraventricular conduction abnormalities. In addition, imipramine had a potent antiarrhythmic action in patients who were recovering from depression. Ten of 11 patients who had more than 10 VPDs/hour had 90% or greater arrhythmia suppression during antidepressant treatment with imipramine at plasma concentrations ranging from 100-302 ng/ml. TRICYCLIC ANTIDEPRESSANT DRUGS (TCAs) have been used clinically to treat depression for more than 20 years. Electrocardiographic effects of TCAs have been reported in reviews, case reports and clinical studies.'1-2 A number of TCAs prolong the PR, QRS and QTc intervals and cause ST-T-wave changes after overdose.1 3, 4-6, 8 IIt is not clear whether these ECG changes occur commonly at therapeutic plasma concentrations; nor is it clear whether ECG changes are more likely to occur in patients with preexisting heart disease or conduction abnormalities. In 1977, Kantor et al.13 reported a 74-year-old man with preexisting right bundle branch block (RBBB) and right-axis deviation (+ 140°) who developed high-grade atrioventricular (AV) block at therapeutic imipramine plasma concentrations. This case suggests that patients with preexisting conduction abnormalities may be more susceptible to imipramine's effects on AV conduction. Other reports warn that TCAs should be used cautiously or avoided entirely in patients with ECG abnormalities or heart disease because they prolong AV and intraventricular conduction." 2, 6, , 14 One goal of the present study was to determine the ECG effects of imipramine at antidepressant plasma concentrations; another goal was to determine whether imipramine had an an- tiarrhythmic effect in depressed patients with ventricular premature depolarizations (VPDs). The second goal stemmed from an early, unexpected finding in this study that imipramine diminished the frequency of VPDs. Two patients (1 and 5) were among the first of the 44 patients enrolled in the present study and formed the basis of the report that suggested that imipramine had antiarrhythmic properties.'5 However, the current literature" 2, 14, 16 and the package insert17 state that imipramine is likely to induce VPDs. To accomplish these two objectives, we studied 44 depressed patients who were participating in a 6-week study of the relationship between the antidepressant effect of imipramine and its plasma concentration.
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Methods
Fifty-five patients with the diagnosis of depression were admitted to a 14-bed unit at the New York State Psychiatric Institute to participate in an imipramine efficacy study for depression. The study was designed to establish the likelihood of an antidepressant response when plasma imipramine concentration was kept in a previously determined therapeutic range. After giving informed written consent, each patient began a 6-week, single-blind protocol that included 2 weeks of control, an initial drug-free week and a week of placebo treatment. Then, imipramine was given orally for 4 weeks (initial dose 3.5 mg/kg/day). The protocol required that the dose be adjusted to produce effective antidepressant plasma concentrations. Thus, the imipramine dose was increased by 0.5-2.0 mg/kg/day in the second drug treatment week if plasma imipramine plus desmethylimipramine concentration was less than 150 ng/ml.
Plasma imipramine and desmethylimipramine concentrations were measured three times a week by the method of Perel et al. '8 Because imipramine is extensively metabolized to desmethylimipramine, which is also an active antidepressant compound, we expressed VOL 60, No 5, NOVEMBER 1979 plasma concentration as the sum of the plasma imipramine and desmethylimipramine concentrations. Therefore, the sum of these two compounds was used to define the therapeutic antidepressant levels in this report. Recently, it has been reported that two other metabolites of imipramine, 2-hydroxyimipramine and 2-hydroxydesmethylimipramine, are found in the plasma of patients taking imipramine. We attempted to measure the concentration of the hydroxymetabolites in this study by the method of Stiller et al. '9 During each week of the protocol, the following recordings were obtained: 1) a standard 12-lead ECG to determine the PR interval and T-wave amplitude; 2) high-speed, high-fidelity recordings to measure the QRS and QT intervals; and 3) a 24-hour continuous ECG (Avionics Model 400 recorder) to determine the heart rate and the frequency of VPDs. These records were coded and the PR, QRS and QT intervals and Twave amplitude measured without knowledge of the study week. The weekly mean duration of the PR interval was determined by measuring 10 Abbreviations: NKHD = no known heart disease; ASHD = arteriosclerotic heart disease; HCVD = hypertensive cardiovascular disease; UHD = unknown heart disease; RHD = rheumatic heart disease; APD = atrial premature depolarization; VPD = ventricular premature depolarization; placebo week, 2) mean of drug-free and placebo weeks vs mean of the 4-week drug treatment, and 3) a contrast designed to test for linear trend during the four drug weeks. When divided by their appropriate standard errors, the contrasts yielded t statistics that were used to assess significance levels.22
Results
Of the 55 patients who were admitted to the depression unit for this study, 11 dropped out. Four patients withdrew before drug treatment because of a spontaneous improvement in depression. Seven others began drug therapy but withdrew later because of complications related to imipramine or other medical/psychiatric problems: one became agitated while taking imipramine, three had symptomatic orthostatic hypotension, one developed a tremor, and two were reclassified as psychotic. Forty-four of the 55 patients who enrolled completed the entire 6-week protocol. The clinical characteristics of these 44 patients are summarized in table 1. Seventeen patients were male and 27 were female, and ranged in age from 34-76 years (59 ± 11 years, mean ± SD). Sixteen patients had heart disease and 28 did not. Thirty patients had ECG abnormalities on their standard 12-lead ECG taken during the control weeks; 14 of these patients had conduction abnormalities (table 1) . Four patients had RBBB and one had left bundle branch block (LBBB); five had left anterior fascicular block (one of these also had RBBB); three had first-degree AV block; and two had first-degree AV block and incomplete RBBB (table 1 ). In addition, 11 patients had an average of more than 10 VPDs/hour recorded in their two control 24-hour Holter ECG tapes.
ECG Effects of Imipramine
Changes in the PR, QRS and QTc intervals, Twave amplitude and 24-hour average heart rate for the 44 patients during the 6-week clinical trial were subjected to statistical analysis using the analysis of variance and analysis of contrasts as described in the Methods.2' We reached three conclusions regarding imipramine's ECG effects. First, there was no significant difference between the control and placebo weeks for any of the variables (t test). During each of the two control weeks, these variables were remarkably constant ( fig. 1, table 2) .
Second, all of the variables showed a significant drug effect, i.e., the mean of the control and the placebo weeks was significantly different from the mean of the 4 weeks of imipramine treatment (t test the PR, QRS and QTc intervals, heart rate and Twave amplitude were analyzed for the 44 subjects during the study weeks. There was much intersubject variability in the regression slopes among the 44 subjects. After the individual regressions of the 44 subjects were analyzed and a mean slope was obtained, a significant relationship was observed between the PR interval (p < 0.02), QRS interval (p < 0.001) and the heart rate (p < 0.01) vs the imipramine plus desmethylimipramine concentration. There was no significant regression of the QTc interval and T-wave amplitude on the plasma tricyclic concentration. The mean correlation coefficients among the ECG variables and imipramine and desmethylimipramine concentration were: PR, r = 0.349; QRS, r = 0.355; QTc, r = 0.123; and heart rate, r = -0.235. Table 2 lists the mean weekly ECG measurements vs the mean plasma imipramine plus desmethylimipramine concentration for the 44 patients.
We attempted to account for all the metabolites of imipramine, including the hydroxymetabolites, 2-hydroxyimipramine and 2-hydroxydesmethylimipramine (see Methods). These two compounds have recently been found in the plasma of patients taking imipramine19 and have myocardial depressant effects in dogs.23 While the chromatographic method used is suitable for separating and quantitating the hydroxymetabolites, problems related to the collection tubes, storage and preparative steps made the analysis of the hydroxymetabolites unreliable. There was so much variance in replicate measurements that the data on the hydroxymetabolites were discarded. Studies to measure the hydroxymetabolites in plasma and urine of man and to determine their contribution to the ECG effects of imipramine are needed.
Change in PR as a Function of Baseline PR In order to test whether patients with a long PR interval before drug therapy had greater increases in PR interval during treatment, the change in this variable (treatment vs pretreatment) was plotted for each subject as a function of the PR interval before therapy ( fig. 2) short pretreatment QRS (< 100 msec). The 14 subjects with a pre-imipramine QRS duration of 100 msec or more had no greater mean increase in QRS (9.2 + 6.1 msec) than the 30 subjects with a predrug QRS duration less than 100 msec (7.7 ± 10.9 msec).
Effect of Imipramine on Ventricular Arrhythmias
Eleven of the 44 patients averaged more than 10 VPDs/hour in two control 24-hour Holter recordings, one recorded during the drug-free and one during the placebo week. The two control records were similar for frequency of VPDs (tables 3 and 4) . The effect of imipramine on VPD frequency was evaluated in these 11 patients. Table 3 outlines the frequency of VPDs during each week of the study for the 11 patients with more than 10 VPDs/hour. Over the course of drug treatment, each of the patients had a decrease in the frequency of VPDs. Ten of the 11 patients had greater than 90% improvement in their ventricular arrhythmia during treatment with imipramine at concentrations ranging between 100-302 ng/ml ( sense. Table 6 summarizes the time course for the clinical response of depression and arrhythmia suppression for the 11 patients who had more than 10 VPDs/hour. Depression outcome was assessed after weekly patient conferences were held and a Hamilton score was determined. Hospitalized, depressed patients had initial Hamilton scores of 20-35. Patients who are completely recovered from depression have scores of 5 or less.24 By these criteria, nine of the 11 patients had significant improvement in depression. Patients 4 and 19 had no significant improvement in their depressive illness and had final Hamilton scores of 15 and 21, respectively. Nonetheless, both patients had greater than 95% suppression of VPDs. In general, imipramine's effect on VPDs occurred earlier than its antidepressant effect (table 6 ). For example, for eight of the 11 patients a significant decrease, i.e., greater than 80% suppression in VPDs, occurred by the third or fourth week of the protocol (first or second week of imipramine treatment). On the other hand, only one patient had an improvement in depression by the fourth week, eight did not improve until the fifth or sixth week, and two had not fulfilled the criteria for improvement at the end of the study. In patient 5 we had the opportunity to evaluate a 24-hour Holter ECG recording made 10 months after hospital discharge. He had fully recovered from depression and was taking no medications. This postdepression recording revealed 104 VPDs/hour, approximately the same VPD frequency recorded on the control ECG tracings when he was depressed. Further studies are required to confirm the hypothesis that imipramine is antiarrhythmic in nondepressed patients. Discussion ng/ml. During the last week of the study, he had only 25% reduction in VPD frequency and the drug concentration was 151 ng/ml. Our protocol did not permit dose ranging against arrhythmias. It is possible that greater arrhythmia suppression could have been achieved at higher imipramine doses.
During the two control weeks, 33 of the patients had fewer than 10 VPDs/hour (table 4). Nineteen patients had no VPDs and 14 patients had fewer than 10 VPDs/hour. During imipramine treatment, 25 of these patients had no VPDs and seven had fewer than 10 VPDs/hour. Only one patient of the 33 (3%) (patient 36) had some increase in VPD frequency during imipramine treatment. This patient had an average of 3 VPDs/hour during the 2 control weeks; during the 4 weeks of imipramine treatment, VPD frequency increased to 4, 7, 21 and 18 VPDs/hour.
Three other patients (nos. 3, 15 and 31) who had no VPDs during the control weeks developed VPDs on imipramine. VPD frequency for these three patients ranged from 0-5 VPDs/hour while on imipramine (table 4) .
The antiarrhythmic effect of imipramine in depressed patients could be due to relief of depression rather than to an antiarrhythmic effect in the usual In this study, antidepressant doses of imipramine (1.7-7.2 mg/kg/day, mean 3.7 ± 1.0 mg/kg/day) frequently prolonged the PR, QRS and QTc intervals, increased heart rate, and lowered T-wave amplitude. The increase of the PR interval can probably be attributed to prolongation of the HV interval. '6 However, a few subjects had such large increases in the PR interval ( fig. 2 ) that an increase in HV interval alone seems unlikely; this finding suggests that AV nodal conduction delay may also occur in a few patients. However, no clinical electrophysiologic studies have shown that TCAs produce AV conduction delay, i.e., increase the AH interval."6 Another important question is whether patients with preexisting bundle branch disease are at increased risk of AV block during TCA therapy. Fourteen of the 44 patients (32%) in the present study had preexisting conduction abnormalities. The increases in either PR or QRS duration in these 14 (5) 10 (5) 100 (6) Decrease in VPD frequency (%)
100 (3) 100 (3) 83 (4) 98 (5) 93 (4) 91 (3) 100 (3) 100 (3) 100 (3) 47 (4) Imipramine has a half-life of elimination that ranges from 12-30 hours, indicating that effective plasma imipramine concentrations could be maintained without large fluctuations on a twice-a-day dosing schedule. Such a schedule would be a significant advance over currently available antiarrhythmic drugs. Imipramine has been used to treat depression for more than 20 years, thus, its acute and chronic adverse effects are well known, unlike new antiarrhythmic drugs available for clinical trials. If imipramine can be tolerated at the outset of therapy, it is well tolerated for long periods of time. It is not yet clear whether imipramine's antiarrhythmic action in depressed patients with VPDs is a consequence of its antidepressant effects or of a direct cardiac action. It is possible that depression promotes ventricular arrhythmias and that imipramine works entirely by its antidepressant effect; if so, imipramine might be totally ineffective as an antiarrhythmic against VPDs in patients who are not depressed. The antiarrhythmic efficacy of imipramine in non-depressed cardiac patients with VPDs should be evaluated in order to clarify the mechanism of imipramine's VPD suppressant action and determine whether cardiac patients with ventricular arrhythmias will benefit from imipramine therapy. 
